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Abstract
Breakthrough cancer pain has attracted more and more attentions recently 
because it has become the biggest obstacle to control cancer pain. Pain can occur at 
any stage of cancer. Despite the aggressive treatment, some patients still experience 
high-intensity pain in the short term, which is commonly referred to as break-
through pain. Typical breakthrough pain has clinical features such as rapid onset 
and short duration, and it has uncontrollable and unpredictable characteristics, 
which impact the overall life quality of patients and the therapeutic effect of cancer 
pain. It has always been a puzzle and difficult in clinical treatment of breakthrough 
cancer pain. This paper aims to provide a more detailed review of the definition, 
assessment tools, classification and characteristics, epidemiology, and mechanism 
and treatment of breakthrough cancer pain, in order to facilitate the future devel-
opment of this work in clinical treatment.
Keywords: breakthrough cancer pain, characteristics, mechanisms, therapy
1. Introduction
Pain is one of the most common clinical symptoms associated with malignant 
tumors. Thirty to forty percent of patients suffer from pain at the beginning of 
diagnosis [1]. In actively treated patients, this proportion is higher, accounting 
for 50%, and in advanced cancer, even up to 90% [2]. Although it can effectively 
control the background pain of most cancer patients according to the WHO three-
step analgesic principle, it still suffers from cancer pain. Cancer patients, indeed, 
may suffer from intense pain spikes that break through the control of chronic pain. 
Uncontrollable and unpredictable characteristics of a complex manifestation of 
cancer pain, termed as breakthrough cancer pain (BTP), have always baffled the 
treatment and the adverse effects including diet, sleep, daily activities, relationships 
with others, aggravating depression and anxiety and will impact patients’ quality 
of life. Therefore, the control of breakthrough cancer pain is still a very difficult 
problem for clinicians. In view of the current lack of research data on outbreak pain 
in China, this paper aims to provide a more detailed review of the breakthrough 
cancer pain, in order to facilitate the future development of this work in clinical 
treatment.
2. The definition of breakthrough cancer pain
Background pain in cancer patients manifests as a persistent state of pain (most 
commonly 12 hours or longer), usually controlled by long-term administration. 
According to the WHO three-step analgesia program, general background cancer 
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pain can be adequately controlled in 70–90% of patients [3]. Despite good control 
of baseline pain, some patients have short-term, short-lived, intense pain episodes. 
This is called breakthrough cancer pain (BTP) [4].
The first definition of cancer pain is proposed by Portenoy and Hagen in 1989 as 
the following: BTP is a transient increase in pain, greater than moderate intensity, 
occurring on moderate- or lower-intensity baseline pain [5]. In the third edition of 
Oxford palliative medicine textbook, BTP is defined as a transient deterioration of 
pain experienced by patients with relatively stable and well-controlled baseline pain 
[6]. In 2009, the UK and Ireland Conservative Treatment Collaborative Committee 
(APM) put forward the following views on outbreak pain and concluded that as 
long as the following three conditions are met at the same time, it can be diagnosed 
as an BTP: (1) having background cancer pain, (2) the background cancer pain 
adequately controlled in the last week (NRS score ≤ 3 points), and (3) the pain 
temporarily acutely aggravated [7].
3. Evaluation tools for breakthrough cancer pain
For cancer patients, the intensity of pain should be assessed at each visit. The 
most common is the numerical score (NRS). The pain intensity level from 0 to 10 is 
evaluated as 0 indicating lack of pain (no pain) and 10 indicating the most extreme 
pain (the most imaginable pain). Visual analog scale (VAS) is also frequently used; 
patients use a 100 mm length digital scale to describe pain intensity (0, no pain; 
100, the most powerful pain imaginable). The descriptive Likert scale (painless, 
mild pain, moderate pain, strong pain, severe pain) is the least accurate but is usu-
ally the most understandable for the patient.
But general tools may not be sufficient to adequately cover the complexity of 
BTP. Several specific features of BTP are reflected in background pain, treatment-
related factors (including trigger events and predictability), and time factors. Key 
factors include relationship to background pain, time to last BTP, frequency, peak 
pain intensity, position, time from onset to maximum intensity, duration, cause, 
predictability, general remission, BTP relief, pain satisfaction with relief, the onset 
of pain relief, and satisfaction with the onset of pain relief. Other items completed 
by professionals include the etiology of BTP and the pathophysiology of BTP 
[8]. Understanding these factors is critical to being able to construct an effective 
analgesic strategy, which is the primary purpose of any pain assessment. The lack of 
BTP assessment tools may be related to the fact that some authors advocate the use 
of general pain tools without the need for a separate BTP assessment tool [9, 10]. 
Recently, a new evaluation tool was developed and validated for BTP (Webber’s BAT 
tool). The assessment tool provides information about BTP and how the efficacy 
and toxicity of BTP drugs interfere with everyday life, and the reliability and 
effectiveness of testing in a group of patients is quite good [11].
Portenoy et al. used the Beck Depression Scale (BDI) questionnaire, the beck 
anxiety scale (BAI) questionnaire, and the baseline pain intensity measurement 
based on the VAS scale to assess the impact of BTP on quality of life. In 178 patients 
with well-controlled baseline pain, both groups were extracted and evaluated based 
on whether they had BTP. In 65% of patients, BTP is caused by cancer, and in other 
cases it is related to the treatment used. Baseline pain is more severe in patients with 
BTP. In addition, how pain affects mood, work, sleep, mobility, social relationships, 
and life satisfaction is also assessed. Each aspect is evaluated over a range of values 
from 0 to 10 (0, no effect; 10, overall impact). In the case of the BDI and BAI scales, 
the patient responded to 21 questions, ranging from 0 to 3 (0 for asymptomatic and 
3 for highest symptom intensity) [12].
3Breakthrough Cancer Pain
DOI: http://dx.doi.org/10.5772/intechopen.84581
It is worth noting that BTP may have a negative impact on prognosis [13] and 
may also have an adverse effect on the duration of cancer treatment [14]. Accurate 
diagnosis of pain types and early introduction of appropriate treatments should 
be sought. Moreover, in the lack of exhaustive tools, successful BTP diagnosis (and 
management) is the result of the combination of adequate assessment, appropriate 
(tailored) treatment, and adequate reassessment.
4. Classification and characteristics of breakthrough cancer pain
Breakthrough cancer pain can be divided into sporadic pain (incidental pain), 
spontaneous or idiopathic pain, and discontinuation of drug withdrawal (end of 
dose). Mixing BTP can also be included as the fourth subtype [15]. Sporadic pain is 
a common type of BTP, with a shorter peak intensity and a shorter duration, more 
predictable, often caused directly after muscle or bone activity, such as getting up, 
turning over, going to toilets, coughs, etc. It can also be associated with contraction 
or spasm of visceral smooth muscle, such as bowel or bladder spasm, so patients are 
more willing to limit their activity to avoid triggering BTP, although the duration of 
pain is unpredictable even after cessation of activity. There is no obvious cause of self-
explosive pain, and the duration of pain is more than 30 minutes. It is generally not 
directly related to regular analgesic treatment and has no significant correlation with 
physical activity [16]. In general, when there is sufficient analgesia for most of the day, 
three to four episodes per day are considered acceptable [17]. Insufficient analgesic 
drugs are relatively rare. It often occurs at the next point in the continuous analgesic 
treatment phase for 1–2 hours, and acute pain occurs on the basis of continuous pain 
treatment. APM believes that the analgesic drug dose-deficient outbreak is caused by 
insufficient control of the underlying cancer pain and that it is not a BTP [7].
BTP is characterized by a rapid onset, usually occurring in a matter of minutes 
or even seconds (average about 3 minutes), stronger than baseline pain, up to 7 
points (NRS score), and very short duration (average 30 minutes) [1]. In a large 
study of 1412 patients, 80.6% of patients reported a significant negative impact of 
BTP on daily life. The average number of episodes was 2.4 per day with an average 
intensity of 7.4/10. In patients reporting a rapid onset of BTP, this is predictable in 
approximately half of the cases, while BTP with a gradual onset (>10 minutes) is 
less predictable. The average duration of an untreated episode of BTP was approxi-
mately 30 minutes [10]. These characteristics may change during the course of the 
disease. For example, patients who are receiving palliative care are older, have lower 
levels of Karnofsky, have fewer BTP episodes per day, and have slower BTP episodes 
than those assessed in the pain clinic or oncology ward. BTP is less predictable [18].
Davies et al. published the results of a multicenter clinical trial involving 1000 
patients treated in 28 professional palliative care units in 13 European countries 
from 2008 to 2011. Patients were classified as eligible for trial according to a ques-
tionnaire on five questions. Forty-four percent of patients were induced by specific 
factors, 41.5% were idiopathic, and 14.5% were mixed. The results showed that 
specific factors caused by BTP patients’ activity problems and basic daily activities 
were more frequent, while those with idiopathic pain were more common with 
changes in mood and sleep problems [18].
5. Epidemiology of breakthrough cancer pain
There are wide variations in the estimates of incidence reported in the litera-
ture, possibly due to the different backgrounds and implications of the definition 
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of BTP. A multicenter study in the four Nordic countries in 201,135 surveyed the 
incidence of BTP in 320 patients with cancer pain by issuing questionnaires, all 
from palliative care centers or pain treatment centers. Of these, 83% had break-
through cancer pain, in which 44% had sporadic outbreaks, 39% had spontaneous 
outbreaks, and 17% had both types of pain. On average, there were three outbreaks 
of pain every 24 hours. The longest interval was 2 times/week, and the shortest 
interval was 24 times a day. According to the degree of pain, 3% of patients were 
mild, 37% were moderate, and 60% were severe [8].
In some epidemiological studies, although not verified, the patient’s background 
pain may be uncontrolled or not receiving opioids. For example, in more than half of 
patients with severe background pain, a different phenomenon than other patients 
was observed, and patients without BTP had higher background pain intensity. In 
other studies, most patients had uncontrolled background pain, who received non-
opioid analgesics or weak opioids or were dissatisfied with pain management.
6. Mechanisms of breakthrough cancer pain
The pathogenesis of cancer pain is very complicated. The most common causes 
are malignant tumor compression and infiltration of pain-sensitive organ structures 
such as bones, muscle soft tissue, peripheral nerves, internal organs, and the others. 
There is also atrophy and cancer cachexia, or it may be the result of aggressive 
anticancer treatment, but the real cause in some patients is unclear [19].
The most common nociceptors associated with cancer pain are afferent nerves, 
which can transmit various noxious stimuli to the central nervous system through 
the periphery. Nociceptors mainly have two major functions: transduction of 
pain signals and transmission of pain signals. Various noxious stimuli can directly 
activate the nociceptors, transmitting the electrochemical nerve impulse signals 
generated by the afferent nerves to the central nervous system of the patient, and 
the patient has a feeling of pain. Cancer and immune cells in the tumor mass region 
release several neuroimmune mediators that interact with multiple receptors on 
peripheral nociceptive nerve terminals to promote abnormal discharge and hyper-
excitability. In addition, tumors that grow near the peripheral nerve can impair the 
integrity of the nerve and induce neurological conditions associated with persistent 
pain, hyperalgesia, or allodynia. Both of these effects of the tumor on the peripheral 
nerves can lead to central sensitization, which further enhances the efficacy of noci-
ceptive transmission through the spinal dorsal horn and the perception of BTP [20].
During the operation, tissue damage associated with damage to the surrounding 
small nerves can be caused. After tissue damage, inflammatory mediators and other 
substances (e.g., histamine, serotonin, nerve growth factor, bradykinin, leukotri-
enes, prostaglandins, norepinephrine, cytokines, etc.) are damaged at the wound 
site tissue and inflammatory cells, and sympathetic nerve endings are released. The 
released material can alter the excitability of nociceptors by phosphorylating and 
upregulating the cell membrane or upregulating ion channels in the nerve. This 
peripheral sensitization can explain the increased sensitivity of early postopera-
tive clinical manifestations to mechanical stimulation of the wound site. However, 
postoperative pain cannot be explained only by peripheral mechanisms. Repetitive, 
detrimental input from sensitized C fibers causes activation of the signal cascade 
within the dorsal horn cells, thereby facilitating the response. Central sensitization 
may explain the increased sensitivity of noninvasive tissue around the wound to 
mechanical stimulation. Under these conditions, mechanical stimulation caused by 
exercise and cough may cause BTP [21].
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Recent studies have found that specific nuclei located in the posterior thalamus 
are associated with pain-related networks. Related studies have found that the 
most effective inhibitors of noxious stimuli are β-endorphin, enkephalin, and 
dynorphin. The most common precursor of β-endorphin is proopiomelanocortin; 
the precursor of enkephalin and leucine enkephalin is mainly proenkephalin-A 
(pro-ENK); the precursor of dynorphin is enkephalin original B. Β-Endorphin 
mainly binds to opioid receptors, and enkephalin mainly binds to opioid receptors, 
and dynorphin mainly binds to opioid κ receptors. The commonly used opioids, 
oxycodone and morphine sustained-release tablets, are combined with receptors 
and/or K receptors to mimic the action of endogenous opioid peptides to achieve 
analgesic treatment [22].
Visceral pain may be located in the visceral or distant body parts. Two types of 
nociceptors dominate the internal organs: high threshold receptors and intensity-
encoded mechanoreceptors. In addition, the presence of “silent” nociceptors has 
been found. “Silent” nociceptors are activated in the event of tissue damage or 
inflammation and may contribute to the signaling of chronic visceral pain. High 
threshold nociceptors may be activated in acute pain states. For example, prolonged 
stimulation of the internal organs, such as inflammation, may sensitize high 
threshold nociceptors and activate “silent” nociceptors. Sensitized nociceptors may 
now also respond to harmless stimuli. Increased peripheral neuronal activity results 
in increased excitability in the visceral-somatic neurons in the spinal cord (central 
sensitization). For example, BTP caused by food intake can be explained by sensiti-
zation of visceral mechanoreceptors, and the increase in pain area is due to central 
sensitization [23].
Our team found that the activation of astrocytes in the dorsal horn of spinal 
cord and connexin 43 (Cx43) protein is involved in the process of bone pain in bone 
metastases in mice. The total amount of Cx43 protein and phosphorylation may 
be important factors affecting cancer outbreak pain factor. Gap 26 blocks the gap 
junction channel of the spinal dorsal horn, which can improve the pain behavior 
index of mice with cancerous outbreak pain and downregulate the expression of 
Cx43 protein, which can regulate the pain of cancerous outbreak. The spinal dorsal 
horn EAAT1 protein is involved in the pathogenesis of mouse basic cancer pain, and 
EAAT2 protein has an effect on the occurrence and maintenance of bone metasta-
ses. Activation of EAAT2 by Cef improves its pain behavioral metrics and regulates 
burst pain. Cx43 can affect the protein expression of EAATs but EAAT2 does not 
affect the expression of Cx43 protein. Spinal dorsal horn Cx43-EAATs may play a 
role in cancerous outbreaks [24].
7. Treatment of breakthrough cancer pain
Treatment with BTP includes medication, nerve block, nerve damage, TNES, 
palliative exposure to bone lesions, the use of bisphosphonates, and identification 
and prevention of factors that induce BTP (e.g., excessive physical labor, persistent 
cough, constipation). The NCCN guidelines for adult cancer pain [25] recom-
mends the use of 10–15% of immediate-release opioids in total daily analgesics to 
treat BTP. If the number of outbreaks of pain per day exceeds 4 times, the amount 
of the basic analgesic drug is raised. Opioid analgesics have no ceiling effect. For 
severe refractory pain, high-dose opioid controlled-release preparations are often 
needed for analgesic treatment. Large doses are defined as daily doses of oxycodone 
sustained-release tablets (or equivalent doses of other opioid analgesics such as 
fentanyl transdermal patches or MS contin) up to 150 mg/d.
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7.1 Drugs
Opioids are still the most important and effective drugs for the treatment of 
breakthrough cancer pain [26]. The main opioids currently used to treat BTP 
are morphine immediate-release tablets, oxycodone sustained-release tablets, 
fentanyl sublingual tablets (SLF), morphine sustained-release tablets and 
controlled-release tablets, fentanyl nasal spray (INFS), fentanyl transmucosal 
citrate (OTFC), morphine sulfate (injection), sufentanil injection (injection), 
and so on. The above various types of morphine agonists work in combination 
with secretory opioid receptors, which produce analgesic effects after agonizing 
the receptor.
Oral administration is the most common route of administration for cancerous 
outbreaks and is the recommended route of administration by the WHO. The NICE 
guidelines recommend immediate-release of morphine for BTP first-line first-aid 
drugs and do not provide fentanyl as a first-line rescue drug but morphine. The 
onset and duration of immediate-release tablets may not be suitable for the treat-
ment of many BTP events [27]. Oxycodone sustained-release tablets can be used 
as a two-step drug or as a three-step analgesic drug, which can simultaneously 
agonize both receptors and K receptor opioid receptors, with high bioavailability 
and clinical good analgesic effect and less drug-related adverse reactions [22]; the 
analgesic intensity is about twice that of morphine immediate-release tablets. After 
oral administration, there will be two release phases, which provide early onset of 
rapid analgesia. The fast release phase and the subsequent sustained-release phase, 
through the rapid release phase to achieve the purpose of treating burst pain, do not 
require conversion of the dosage form; clinical application of oxycodone controlled-
release tablets is more and more extensive.
In order to evaluate the efficacy of oral morphine and oral transmucosal fentanyl 
preparations to provide further insight into their relative merits as treatments for 
BTP, we conducted an analysis to compare the effects of fentanyl, morphine, and 
placebo on BTP indirectly (Table 1, Figures 1–6). The therapeutic effect was evalu-
ated by the difference in pain intensity difference (PID) score. We found that all 
opioids provided better analgesic effects during the first hour after dosing, whereas 
fentanyl may provide a higher level of pain relief than oral morphine. Participants 
administered a transmucosal fentanyl showed lower pain intensity and higher pain 
relief at all time points than placebo or oral morphine, and the fentanyl achieved 
significant pain relief faster. But there is no significant difference between the vari-
ous transmucosal fentanyl preparations. From the PID score, the analgesic effect 
of fentanyl is stronger than oral morphine. And improvements in pain relief were 
apparent within 30 minutes of treatment, with the PID being larger for the fentanyl 
preparations than for MSIR during this period. This is of potential importance 
because most BTP episodes occur within 30 minutes. However, there are few exist-
ing studies, especially regarding the comparison of fentanyl with oral morphine, 
which is a limitation of this mixed treatment. Moreover, the possibility of system-
atic differences between undetected data sources for heterogeneity analysis cannot 
be ruled out. In conclusion, although oral morphine is still an appropriate treatment 
option for BTP, oral transmucosal fentanyl may be more clinically advantageous in 
some patients.
The recently published guidelines support this approach and recommend the 
use of fast- or short-acting opioids to treat BTP, whose pharmacodynamics reflect 
the rapid onset and short duration of pain [28]. The Cochrane review reported the 
utility of seven different transmucosal fentanyl compared to oral opioids. Oral and 
nasal transmucosal fentanyls are an effective treatment for BTP [29]. The drugs 
such as fentanyl oral effervescent tablets and fentanyl sublingual tablets have also 
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Fentanyl (F) and placebo/morphine PID (C)
Study 5 minutes 10 minutes 15 minutes 30 minutes 45 minutes 60 minutes
F C F C F C F C F C F C
INFS vs. placebo
(HANS2009 [33])
N N 2.58 1.22 N N N N N N 4.57 2.46
INFS vs. placebo
(RUSSELL2010 [34])
0.59 0.49 1.32 0.93 1.96 1.33 2.69 1.73 3.19 2.08 3.57 2.21
INFS vs. placebo
(MORTEN2015 [35])
N N 2.4 1.5 N N N N N N N N
INFS vs. IRMS
(FALLON2011 [36])
1 1 2.02 1.8 3.22 2.68 4.38 3.64 4.95 4.47 5.58 5
SFT vs. placebo
(NAOHITO2015 [37])
N N N N 2.43 2.06 4.11 3.39 N N 5.58 4.52
SFT vs. placebo
(RANCK2009 [38])
N N 1.2 0.92 2.04 1.51 2.94 2.1 N N 3.45 2.51
SFT vs. placebo
(NOVOTNA2014 [39])
0.7 0.5 1.6 1.1 2.6 1.8 3.5 2.5 N N 3.9 2.7
SFT vs. placebo
(NAOHITO2015 [40])
N N N N N N 3.18 2.7 N N N N
OTFC vs. placebo
(RAUCK2009 [41])
0.3 0.3 0.8 0.7 1.4 1.2 2.5 1.9 3 2.3 3.3 2.4
OTFC vs. IRMS
(PAUL2001 [42])
N N N N 1.86 1.46 2.88 2.4 3.55 3.03 4.03 3.57
Table 1. 
META analysis data
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Figure 3. 
Fentanyl versus placebo/morphine PID 15 minutes.
Figure 4. 
Fentanyl versus placebo/morphine PID 30 minutes.
Figure 1. 
Fentanyl versus placebo/morphine PID 5 minutes.
Figure 2. 
Fentanyl versus placebo/morphine PID 10 minutes.
Figure 5. 
Fentanyl versus placebo/morphine PID 45 minutes.
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been approved for use in European and American countries. However, the state of 
oral mucosa, drug distribution, and oral infections will affect the absorption of 
drugs, thus affecting the analgesic effect of drugs. Fentanyl nasal spray (INFS) has 
been approved by the European Commission in 2009 and has been officially used 
in the clinic. It has been marketed globally and is mainly used for outbreak pain in 
cancer patients who maintain analgesic treatment with drugs such as oral opioids. 
Treatment: nasal mucosal sprays are suitable for those with oral mucosal damage or 
saliva dysfunction, but those with nasal mucosal bleeding or ulcers need to switch 
to other treatments [30].
Both morphine sulfate injection and sufentanil citrate injection can be adminis-
tered intravenously. Intravenous use of opioids has a fast onset and a positive effect 
[31, 32]. However, it is necessary to evaluate the pain every 15 minutes, and should 
be alert to the acute side effects of drugs such as respiratory depression [32], vomit-
ing, dizziness, acute urinary retention, etc., especially acute respiratory depression, 
severe cases can be directly life-threatening, so opioid veins The application should 
be performed in a ward with emergency conditions or in an emergency ward, and 
an opiate rescuer naloxone is prepared at the bedside.
Individualized doses and modes of administration can also be tailored to the 
condition, and stable morphine is delivered to the human body via intravenous 
(PCIA), epidural (PCEA), and subcutaneous (PCPA).
7.2 Cell therapy
Cell treatment is to return autologous cells cultured in vitro to patients. Through 
these cells with biological micro-pump function, they can continue to secrete 
analgesic substances to relieve pain or improve pain thresholds, such as serotonin, 
norepinephrine, dynorphin, enkephalin, neurotrophic factor, etc., to achieve the 
purpose of relieving cancer pain or improving the pain threshold of patients. The 
most extensive and intensive research is the analgesic effect of adrenal chromaffin 
cells, sympathetic ganglion cells, and some neurotumor cells.
7.3 Gene therapy
Gene therapy refers to a method of achieving analgesic effects by altering gene 
expression in a patient. It can be divided into in vivo pathways and in vitro path-
ways. In vitro route refers to the removal of target cells from the body or the adop-
tion of cell lines and the in vitro introduction of therapeutic genes into the body for 
therapeutic purposes. In vivo route refers to the direct introduction of therapeutic 
genes into the body. In pain research, there are two main aspects of gene therapy, 
namely, by upregulating anti-pain gene expression and downregulating pain gene 
expression, specifically interfering with the biological behavior of pain for thera-
peutic purposes.
Figure 6. 
Fentanyl versus placebo/morphine PID 60 minutes.
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7.4 Interventional neuroradiologic therapy
Nerve block and nerve damage are one of the main treatments for cancer pain 
by blocking the pain transmission pathway. The current clinical damage treatment 
is damage to peripheral nerves, nerve roots, celiac plexus, subarachnoid space, and 
pituitary gland. Before the operation, physical examination and imaging methods 
were used to fully determine the pain range of the patient, and the nerves to be con-
trolled were determined. Under the guidance of CT, the target nerve was destroyed 
by means of anhydrous alcohol, chemotherapy drugs such as doxorubicin, or 
physical ablation. Analgesic effect, with positive effect, fast onset, and little effect 
on other organ functions, has unique advantages for outbreak pain and intractable 
cancer pain that are ineffective for medical treatment. Currently, nerve blockers 
or lesions often have anesthesiologists, or the implementation of pain specialists 
in specialist hospitals has extremely high requirements for the operation of doc-
tors in the positioning of nerves and imaging; otherwise it is likely to cause serious 
consequences.
8. Summary
Breakthrough cancer pain is a type of problem that clinicians urgently need 
to solve. There is currently no recognized definition and classification system for 
cancer BTP, and there are no well-proven BTP assessment tools that pose significant 
challenges to clinical management. Although breakthrough cancer pain has com-
mon clinical features, there are significant differences between individuals, which 
require clinicians to emphasize the importance of individualized, multidisciplinary 
analgesic programs on the basis of comprehensive treatment. In short, the current 
overall treatment effect of breakthrough cancer pain is not good; it is worthy of our 
attention.
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